Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

26.22 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics

< Previous 1 2 3 4 5 6 Next >
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX< 
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex to Participate in Upcoming November Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
Via Benzinga
Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study
Via Benzinga
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
Celldex Therapeutics (NASDAQ:CLDX) brought in sales totaling $163 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 56.2%, resulting in a loss of $36.00... 
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91%... 
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
The study was in 26 patients with chronic hives that don't respond to antihistamines. 
Via Investor's Business Daily
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF. 
Via InvestorPlace
Celldex Therapeutics: Q4 Earnings Insights
Celldex Therapeutics (NASDAQ:CLDX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
The Secret To Successful Investing In Biotech
Have you ever had a stock jump 30%, 50% or 100% in one day? 
Via Talk Markets
77 Biggest Movers From Yesterday
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares moved upwards by 29.96% to $7.72 during Friday's pre-market session. The company's market cap stands at $20.8... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021
Upgrades According to Macquarie, the prior rating for Turquoise Hill Resources Ltd (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.